Thomas John

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8808239/publications.pdf

Version: 2024-02-01

110 papers	6,104 citations	147566 31 h-index	76769 74 g-index
114 all docs	114 docs citations	114 times ranked	8257 citing authors

#	Article	IF	Citations
1	Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 2020, 382, 41-50.	13.9	1,725
2	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 198-211.	5.1	773
3	Osimertinib As First-Line Treatment of EGFR Mutationâ€"Positive Advanced Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 841-849.	0.8	423
4	Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncology, The, 2009, 10, 1001-1010.	5.1	194
5	The Ability to Form Primary Tumor Xenografts Is Predictive of Increased Risk of Disease Recurrence in Early-Stage Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2011, 17, 134-141.	3.2	147
6	Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Nonâ€"Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1728-1732.	0.5	143
7	Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clinical Epidemiology, 2014, 6, 423.	1.5	139
8	Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP. Cancer Cell, 2013, 23, 618-633.	7.7	136
9	BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death and Disease, 2019, 10, 342.	2.7	125
10	Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. Journal of Clinical Oncology, 2017, 35, 3591-3600.	0.8	121
11	Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.. Journal of Clinical Oncology, 2020, 38, 9501-9501.	0.8	119
12	Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncology, The, 2020, 21, 1213-1223.	5.1	109
13	Correlation of Mutation Status and Survival with Predominant Histologic Subtype According to the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Stage III (N2) Patients. Journal of Thoracic Oncology, 2013, 8, 461-468.	0.5	102
14	Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respiratory Medicine,the, 2017, 5, 891-902.	5.2	92
15	The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma. Journal of Thoracic Oncology, 2017, 12, 850-859.	0.5	83
16	Distinctive localization of antigen-presenting cells in human lymph nodes. Blood, 2009, 113, 1257-1267.	0.6	76
17	Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 1784-1791.	0.5	75
18	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clinical Cancer Research, 2022, 28, 1302-1312.	3.2	74

#	Article	IF	Citations
19	PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. PLoS ONE, 2016, 11, e0153954.	1.1	73
20	Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunology, Immunotherapy, 2009, 58, 1635-1646.	2.0	63
21	Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma. Clinical Cancer Research, 2008, 14, 5173-5180.	3.2	62
22	Understanding Prognostic Gene Expression Signatures in Lung Cancer. Clinical Lung Cancer, 2009, 10, 331-340.	1.1	59
23	Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9512-9512.	0.8	54
24	Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2012, 7, 1513-1521.	0.5	46
25	Characterization of Lymphomas Developing in Immunodeficient Mice Implanted With Primary Human Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1101-1108.	0.5	44
26	Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma. Clinical Cancer Research, 2017, 23, 1060-1067.	3.2	44
27	A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma. Scientific Reports, 2014, 4, 4186.	1.6	37
28	Pharmacogenetic and Germline Prognostic Markers of Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 296-304.	0.5	35
29	Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 1588-1594.	0.5	35
30	Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Nonâ€“Small Cell Lung Cancer (NSCLC). Journal of Immunotherapy, 2016, 39, 202-204.	1.2	33
31	EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. Lung Cancer, 2018, 126, 133-138.	0.9	33
32	ECSA/DPPA2 is an Embryo-Cancer Antigen that Is Coexpressed with Cancer-Testis Antigens in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2008, 14, 3291-3298.	3.2	32
33	The Role of Cancer-Testis Antigens as Predictive and Prognostic Markers in Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e67876.	1.1	31
34	Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing. Lung Cancer, 2017, 107, 22-35.	0.9	30
35	Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibodyâ€“Drug Conjugate. Molecular Cancer Therapeutics, 2020, 19, 2117-2125.	1.9	30
36	Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage <scp>III</scp> nonâ€“small cell lung cancer. Cancer Medicine, 2013, 2, 916-924.	1.3	29

#	Article	IF	Citations
37	A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. Lung Cancer, 2020, 142, 34-40.	0.9	27
38	Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment. Lung Cancer, 2016, 98, 29-32.	0.9	24
39	A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. Cell Death Discovery, 2021, 7, 122.	2.0	23
40	EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Nonâ€“Small Cell Lung Cancer. Clinical Lung Cancer, 2021, 22, e859-e869.	1.1	23
41	Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes. Cancer Epidemiology, 2022, 76, 102080.	0.8	22
42	Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens. International Journal of Cancer, 2014, 135, 1842-1851.	2.3	20
43	NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer. Lung Cancer, 2020, 146, 154-159.	0.9	20
44	Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma. Expert Opinion on Drug Delivery, 2019, 16, 441-451.	2.4	19
45	Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine. Oncotarget, 2014, 5, 2107-2115.	0.8	18
46	Current and Evolving Methods to Visualize Biological Data in Cancer Research. Journal of the National Cancer Institute, 2016, 108, djw031.	3.0	18
47	Do Randomized Acupuncture Studies in Patients With Cancer Need a Sham Acupuncture Control Arm?. Journal of Clinical Oncology, 2013, 31, 2057-2058.	0.8	17
48	Vortex Keratopathy Presumed Secondary to AZD9291. Journal of Thoracic Oncology, 2015, 10, 1807-1808.	0.5	16
49	Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma. Pathology, 2016, 48, 660-665.	0.3	16
50	Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies. Genome Medicine, 2012, 4, 84.	3.6	15
51	Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 296-303.	0.7	15
52	Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma. Translational Lung Cancer Research, 2020, 9, 639-645.	1.3	14
53	Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression.. Journal of Clinical Oncology, 2017, 35, 8514-8514.	0.8	14
54	Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptorâ€“Mutated Nonâ€“Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. Clinical Cancer Research, 2022, 28, 2286-2296.	3.2	14

#	Article	IF	Citations
55	Preâ€•and onâ€treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced nonâ€“small cell lung cancer. Cancer, 2022, 128, 1574-1583.	2.0	14
56	Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance. Biochemical Society Transactions, 2022, 50, 825-837.	1.6	14
57	Lung cancer in 2016: immunotherapy comes of age. Lancet Respiratory Medicine,the, 2016, 4, 947-949.	5.2	13
58	Lung Cancer in Australia. Journal of Thoracic Oncology, 2020, 15, 1809-1814.	0.5	13
59	BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. Cell Death Discovery, 2020, 6, 114.	2.0	13
60	Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. Oncotarget, 2017, 8, 74036-74048.	0.8	13
61	Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: case report. Translational Lung Cancer Research, 2020, 9, 360-365.	1.3	13
62	Imaging immunity in patients with cancer using positron emission tomography. Npj Precision Oncology, 2022, 6, 24.	2.3	13
63	Immune Checkpoint Inhibition With Chemoradiotherapy in Stage III Nonâ€“small-cell Lung Cancer: A Systematic Review and Meta-analysis of Safety Results. Clinical Lung Cancer, 2021, 22, 74-82.	1.1	11
64	Immunotherapy of advanced or metastatic melanoma. Clinical Advances in Hematology and Oncology, 2007, 5, 994-1006.	0.3	11
65	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA. International Journal of Clinical Oncology, 2022, 27, 695-706.	1.0	11
66	The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma. Expert Review of Anticancer Therapy, 2021, 21, 413-424.	1.1	9
67	A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 2766-2778.	1.3	9
68	Paraneoplastic leukocytoclastic vasculitis as an initial presentation of malignant pleural mesothelioma: a case report. Journal of Medical Case Reports, 2012, 6, 261.	0.4	8
69	â€œCancer 2015â€• A Prospective, Population-Based Cancer Cohortâ€”Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic. Journal of Personalized Medicine, 2015, 5, 354-369.	1.1	8
70	Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. Pathology, 2019, 51, 673-680.	0.3	8
71	Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease. Journal of Thoracic Disease, 2019, 11, 1756-1764.	0.6	8
72	Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort. Lung Cancer, 2020, 150, 1-8.	0.9	8

#	Article	IF	Citations
73	Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma. Pharmaceuticals, 2020, 13, 289.	1.7	8
74	Loss of STING expression is prognostic in nonâ€“small cell lung cancer. Journal of Surgical Oncology, 2022, 125, 1042-1052.	0.8	8
75	Re: Gene Expression-Based Prognostic Signatures in Lung Cancer: Ready for Clinical Use?. Journal of the National Cancer Institute, 2010, 102, 1677-1678.	3.0	7
76	Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma. Expert Review of Anticancer Therapy, 2016, 16, 1235-1245.	1.1	7
77	Outcomes for patients with synchronous and metachronous primary lung cancer after diagnosis of head and neck cancer. Head and Neck, 2017, 39, 1544-1549.	0.9	7
78	Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival. Lung Cancer, 2021, 153, 35-41.	0.9	7
79	Immunotherapy in oncogene addicted non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 2736-2751.	1.3	7
80	Digital PCR of Genomic Rearrangements for Monitoring Circulating Tumour DNA. Advances in Experimental Medicine and Biology, 2016, 924, 139-146.	0.8	6
81	Impact of universal immunohistochemistry on Lynch syndrome diagnosis in an Australian colorectal cancer cohort. Internal Medicine Journal, 2019, 49, 1278-1284.	0.5	6
82	PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. Future Oncology, 2022, 18, 1793-1799.	1.1	6
83	Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Nonâ€“Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: BriefÂReport. Clinical Lung Cancer, 2020, 21, e57-e60.	1.1	5
84	Controversies in the role of radiotherapy in pleural mesothelioma. Translational Lung Cancer Research, 2021, 10, 2079-2087.	1.3	5
85	Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis. Lung Cancer, 2021, 154, 113-117.	0.9	5
86	Ventricular metastasis resulting in disseminated intravascular coagulation. World Journal of Surgical Oncology, 2005, 3, 29.	0.8	4
87	Standard of care in immunotherapy trials: Challenges and considerations. Human Vaccines and Immunotherapeutics, 2017, 13, 2164-2178.	1.4	4
88	Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort. Translational Lung Cancer Research, 2019, 8, 167-175.	1.3	4
89	Role of immunotherapy in lung cancer: Preliminary results of new vaccines and immune checkpoint inhibitors. Asia-Pacific Journal of Clinical Oncology, 2015, 11, 2-8.	0.7	3
90	Is Mesothelioma in China Rare or Misdiagnosed?. Journal of Thoracic Oncology, 2017, 12, 607-609.	0.5	3

#	Article	IF	Citations
91	De novo activating epidermal growth factor mutations (<scp>EGFR</scp>) in smallâ€cell lung cancer. Internal Medicine Journal, 2017, 47, 1071-1074.	0.5	3
92	DDR Alterations as a Surrogate Marker for TMB in SCLC â€" Use it or Lose it?. Journal of Thoracic Oncology, 2019, 14, 1498-1500.	0.5	3
93	Finding chinks in the osimertinib resistance armor. Translational Lung Cancer Research, 2020, 9, 2173-2177.	1.3	3
94	Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants. Hereditary Cancer in Clinical Practice, 2021, 19, 33.	0.6	3
95	SMARCB1/INI1-deficient primary lung carcinoma with hepatic metastasis. Pathology, 2022, 54, 817-820.	0.3	3
96	Bronchoepidural Fistula in a Man with Actinomycosis Complicated Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1761-1762.	0.5	2
97	Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials. Oncology, 2019, 97, 270-276.	0.9	2
98	Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer. Lung Cancer, 2022, 163, 14-18.	0.9	2
99	Combination approaches in NSCLC involving immune checkpoint inhibitors. Lung Cancer Management, 2016, 5, 163-171.	1.5	1
100	The ADAM Trial. JAMA Oncology, 2017, 3, 66.	3.4	1
101	LACES and bootstraps: the hunt for prognostic and predictive markers for adjuvant therapy in NSCLC. Translational Lung Cancer Research, 2018, 7, S239-S242.	1.3	1
102	Abstract 743: ABT-806-derived antibody-drug conjugates (ADCs) inhibit growth of malignant mesotheliomain vivo. , 2018, , .		1
103	Testicular metastasis from ALK-rearranged non-small cell lung cancer. Cancer Treatment and Research Communications, 2016, 9, 32-34.	0.7	0
104	Attitudes of patients and physicians on repeat biopsies for lung cancer. Expert Review of Quality of Life in Cancer Care, 2017, 2, 181-202.	0.6	0
105	In Reply to Leone. Journal of Thoracic Oncology, 2018, 13, e22-e23.	0.5	0
106	Personalized Chemosensitivity Assays for Mesothelioma: Are They Worth the Effort?. Clinical Cancer Research, 2018, 24, 1513-1515.	3.2	0
107	Can molecularly targeted therapy cure patients with resected EGFR mutant NSCLC?. Journal of Thoracic Disease, 2018, 10, S1986-S1988.	0.6	0
108	Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC â€" Tarring all Patients With the Same Brush?. Journal of Thoracic Oncology, 2020, 15, 12-14.	0.5	0

#	Article	IF	Citations
109	Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancerâ€"ready for prime time?. Translational Lung Cancer Research, 2020, 9, 1728-1731.	1.3	0
110	Should we screen for lung cancer in Australia?. Medical Journal of Australia, 2013, 199, 586-586.	0.8	0